Pentigetide

Synthetic Pentapeptide (IgE Derived)Rx: ResearchCompound: Withdrawn

Also known as: Gly-Orn-Ser-Ser-Pro, IgE pentapeptide, Pentyde

Educational Only — Not medical advice. Consult a qualified clinician before using any peptide.

Summary

Pentigetide (also known as Gly-Orn-Ser-Ser-Pro) is a synthetic pentapeptide derived from the Fc region of IgE. It was investigated primarily for allergic rhinitis and other IgE-mediated allergic conditions via intranasal administration. Clinical development was discontinued due to insufficient efficacy in pivotal trials.

Mechanism of Action

Inhibits IgE-mediated allergic responses by competitively binding to IgE receptors on mast cells and basophils, thereby preventing IgE-triggered degranulation and release of histamine and other mediators.

Routes of Administration

Nasal

Goals & Uses

  • Allergic rhinitis symptom reductionAllergy / ImmunologyLow
  • Mast cell stabilizationAnti InflammatoryLow
  • IgE-mediated allergy suppressionImmunomodulationLow

Contraindications

  • Hypersensitivity to pentigetide or peptide componentsAllergyHigh

Adverse Effects

  • Nasal irritationLocal/NasalCommon
  • SneezingLocal ReactionCommon
  • HeadacheNeurologicUncommonPain in the head or upper neck

Drug Interactions

  • AntihistaminesLow

Population Constraints

  • Pediatric patientsAgeRelative
  • Pregnant womenReproductiveRelative

Regulatory Status

  • European UnionUnapprovedNo EMA marketing authorization granted. Not commercially available.
  • United StatesUnapprovedInvestigated in clinical trials; FDA approval never obtained. Development discontinued.

Pentigetide was investigated in the US and other jurisdictions but was never approved by the FDA or EMA. Development was halted after Phase II/III trials failed to demonstrate adequate clinical benefit.

Evidence & Sources

No sources recorded yet.

Browse All PeptidesBuild My Stack